Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Beyond The Mask: Innovation & Opportunities For CRNAs

Ciprofol Chronicles: The New Star in Procedural Sedation

11 Feb 2025

Description

This week, we’re shining a spotlight on Ciprofol, a cutting-edge intravenous anesthetic that has been making headlines in both clinical research and operating rooms worldwide. With its innovative formulation and promising safety profile, Ciprofol is poised to transform the landscape of anesthetic practice. Join us as we explore how this new drug compares to established agents like propofol and what it could mean for the future of procedural sedation and anesthesia. Here’s some of what we discuss in this episode: What is Ciprofol, and why are nurse anesthetists buzzing about it? The reduction in dosage isn’t just about using less drug—it has ripple effects. What about its pharmacokinetics? Does it have the same quick onset and recovery profile that we’ve come to rely on with Propofol? How does Ciprofol stack up when it comes to adverse events? We dissect the study—a randomized, double-blind trial conducted in China. Is Ciprofol the future?   Visit us online: https://beyondthemaskpodcast.com/ The 1099 CRNA Institute: https://aana.com/1099 Get the CE Certificate here: https://beyondthemaskpodcast.com/wp-content/uploads/2020/04/Beyond-the-Mask-CE-Cert-FILLABLE.pdf Help us grow by leaving a review: https://podcasts.apple.com/us/podcast/beyond-the-mask-innovation-opportunities-for-crnas/id1440309246 Donate to Our Heart Your Hands here: https://www.ourheartsyourhands.org/donate  Support Team Emma Kate: https://grouprev.com/haloswalk2024-shannon-shannon-brekken

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.